Pharmacokinetics and Tolerability of Meloxicam Gel Compared to Meloxicam Tablets in Healthy Subjects

Inclusion Criteria: * Healthy subjects as determined by results of screening * Signed written informed consent in accordance with Good Clinical Practice and local legislation * Age \>= 18 and \<= 50 years * Broca \>= -20% and \<= + 20 % Exclusion Criteria: * Any findings of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Surgery of the gastrointestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders * Chronic or relevant acute infections * Hypersensitivity to meloxicam and any of the excipients or non-steroidal antirheumatic agents * Intake of drugs with a long half-life (\>24 hours) (\<= 1 month prior to administration or during the trial) * Use of any drugs which might influence the results of the trial (\<= 10 days prior to administration or during the trial) * Participation in another trial with an investigational drug (\<= 2 months prior to administration or during the trial) * Smoker (\> 10 cigarettes or \> 3 cigars or \>3 pipes/day) * Inability to refrain from smoking on study days * Known alcohol abuse * Known drug abuse * Blood donation (\<= 1 months prior to administration) * Excessive physical activities (\<= 5 days prior to administration) * History of hemorrhagic diatheses * History of gastrointestinal ulcer, perforation or bleeding * History of bronchial asthma * Any laboratory value outside the normal range of clinical relevance * History of dermatological diseases * Skin disease and/or skin lesions at the site of planned application For female subjects: * Pregnancy * Positive pregnancy test * Breast feeding